These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19225409)

  • 21. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
    Felsberg J; Erkwoh A; Sabel MC; Kirsch L; Fimmers R; Blaschke B; Schlegel U; Schramm J; Wiestler OD; Reifenberger G
    Brain Pathol; 2004 Apr; 14(2):121-30. PubMed ID: 15193024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas.
    Reddy KS
    Cancer Genet Cytogenet; 2008 Jul; 184(2):77-86. PubMed ID: 18617055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
    J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
    Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
    Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.
    von Deimling A; Louis DN; von Ammon K; Petersen I; Wiestler OD; Seizinger BR
    Cancer Res; 1992 Aug; 52(15):4277-9. PubMed ID: 1353411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
    Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
    Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.
    Molinari C; Iorio P; Medri L; Ballardini M; Guiducci G; Cremonini AM; Cerasoli S; Riccioni L; Faedi M; Mariani GA; Zoli W; Silvestrini R; Calistri D
    Int J Mol Med; 2010 Jan; 25(1):145-51. PubMed ID: 19956913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas.
    Senetta R; Trevisan E; Rudà R; Maldi E; Molinaro L; Lefranc F; Chiusa L; Lanotte M; Soffietti R; Cassoni P
    J Neuropathol Exp Neurol; 2009 Apr; 68(4):425-31. PubMed ID: 19287309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
    Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization.
    Raghavan R; Balani J; Perry A; Margraf L; Vono MB; Cai DX; Wyatt RE; Rushing EJ; Bowers DC; Hynan LS; White CL
    J Neuropathol Exp Neurol; 2003 May; 62(5):530-7. PubMed ID: 12769192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections.
    Burger PC; Minn AY; Smith JS; Borell TJ; Jedlicka AE; Huntley BK; Goldthwaite PT; Jenkins RB; Feuerstein BG
    Mod Pathol; 2001 Sep; 14(9):842-53. PubMed ID: 11557779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors.
    Scheie D; Andresen PA; Cvancarova M; Bø AS; Helseth E; Skullerud K; Beiske K
    Am J Surg Pathol; 2006 Jul; 30(7):828-37. PubMed ID: 16819324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors.
    Trost D; Ehrler M; Fimmers R; Felsberg J; Sabel MC; Kirsch L; Schramm J; Wiestler OD; Reifenberger G; Weber RG
    Int J Cancer; 2007 Jun; 120(11):2368-76. PubMed ID: 17285580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.